来自:中国糖尿病资讯网 编辑:admin|点击数:|2011-08-25
·糖尿病临床研究·
董其娟
作者单位:450003郑州人民医院
【摘要】 目的 评价地特胰岛素(Det)联合瑞格列奈治疗新诊断的2型糖尿病(T2DM)患者的有效性和安全性。 方法 将56例住院治疗的新诊断T2DM患者,随机分为Det联合瑞格列奈组和预混人胰岛素(诺和灵30R)组进行治疗,观察治疗前后的FBG、2hBG、HbA1c、低血糖发生率、体重增加情况和依从性。 结果 治疗12周后,两组患者的FBG、2hBG、HbA1c均较基线显著降低。Det联合瑞格列奈组和预混人胰岛素组,低血糖发生率分别为0.080、0.150,体重增加发生率分别为0.029、0.035,治疗依从率分别为0.893、0.679。 结论 Det联合瑞格列奈治疗,可显著降低新诊断的住院T2DM患者的血糖水平,并且具有较好的安全性和治疗依从性。
【关键词】糖尿病,2型;地特胰岛素;低血糖;体重增加
doi:10.3969/j.issn.1006-6187.2011.08.016
Therapeutic efficacy and safety of insulin detemir plus repaglinide in newly diagnosed type 2 diabetic inpatients
DONG Qi-juan. Department of Endocrinology, People\'s Hospital of Zhengzhou, Zhengzhou 450003, China
【Abstract】 Objective To evaluate the efficacy and safety of insulin detemir combined with repaglinide in newly diagnosed type 2 diabetic inpatients. Methods All 56 T2DM inpatients newly diagnosed were divided randomly into two groups, one treated by insulin detemir combined with repaglinide, the other treated by premixed human insulin 30R. At baseline and the end of trial, FBG,2hPG,HbA1c,glucose target arrival rate,hypoglycemia,weight gain and compliance were observed. Results After 12 weeks of treatment, levels of FBG,2hBG and HbA1c decreased significantly from baseline in both groups(P<0.05), and the two groups got similar glucose control(P>0.05). Compared with the premixed insulin group, insulin detemir combined with repaglinide group had lower hypoglycemia rate and less weight gain, and more patients wanted to continue this treatment protocol(all P<0.05). Conclusions In newly diagnosed type 2 diabetic inpatients, insulin detemir combined with repaglinide treatment would improve glucose control significantly, and got better safety and treatment compliance.
【Key words】Diabetes mellitus,type 2; Insulin detemir; Hypoglycemia; Weight gain
版权所有:《中国糖尿病杂志》社 主管单位:中华人民共和国教育部 主办单位:北京大学
地址:北京市西城区大红罗厂街1号 邮编:100034 电话(传真):010-88505683
中国糖尿病杂志社版权所 京ICP备11029051号-1 Powered by JiuduCMS 技术支持:九度创想